L‐3‐n‐butylphthalide Promotes Neurogenesis and Neuroplasticity in Cerebral Ischemic Rats

CNS Neuroscience and Therapeutics - Tập 21 Số 9 - Trang 733-741 - 2015
Li‐Chao Yang1, Jiang Li1, Shaofeng Xu1, Jie Cai1, Hui Lei1, Dongmei Liu1, Man Zhang1, Xianfang Rong1, Dandan Cui1, Ling Wang1, Ying Peng1, Xiao‐Liang Wang1
1State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Tóm tắt

SummaryAims

This study investigated whether anticerebral ischemia new drug, l‐3‐n‐butylphthalide (l‐NBP), improved behavioral recovery and enhanced hippocampal neurogenesis after cerebral ischemia in rats.

Methods and Results

The middle cerebral artery of rats was blocked for 2 h. The daily oral administrations of 30 mg/kg l‐NBPor vehicle were begun from the second day until the rats were sacrificed. L‐NBPtreatment markedly increased 5‐bromo‐2′‐deoxyuridine (BrdU)‐positive cells in the hippocampal dentate gyrus (DG) of injured hemisphere on day 28 after ischemia. The amount of newborn cells and newly mature neurons was also increased. The expressions of growth‐associated protein‐43 and synaptophysin were significantly elevated in l‐NBP‐treated rats. However, l‐NBPmarkedly reduced the percentage of BrdU+/GFAP+cells. Additionally, the levels of catalytical subunit of protein kinase A (PKA), protein kinase B (Akt), andcAMPresponse element‐binding protein (CREB) were significantly increased, and the activation of the signal transducer and activation of transcription 3 (STAT3) and the expressions of cleaved caspase‐3 and Bax were obviously inhibited by l‐NBP. Consequently, l‐NBPattenuated the behavioral dysfunction.

Conclusions

It first demonstrates that l‐NBPmay improve the behavioral outcome of cerebral ischemia by promoting neurogenesis and neuroplasticity. Activation ofCREBand Akt and inhibition ofSTAT3 signaling might be involved in.

Từ khóa


Tài liệu tham khảo

10.1161/01.cir.0000441139.02102.80

10.1161/01.STR.17.3.472

10.1111/cns.12051

10.1016/j.nbd.2008.12.013

10.1007/s12035-013-8572-x

10.1016/j.jep.2010.01.064

10.7150/ijbs.8571

10.1179/174313209X414533

Cui LY, 2013, Ninety‐day administration of dl‐3‐n‐butylphthalide for acute ischemic stroke: A randomized, double‐blind trial, Chin Med J, 126, 3405, 10.3760/cma.j.issn.0366-6999.20123240

10.1016/S0165-3806(01)00286-3

10.1038/jcbfm.2012.166

10.1124/jpet.106.118760

10.1016/j.neuropharm.2012.02.014

10.1016/S0028-3908(00)00182-9

10.1016/0165-0270(84)90007-4

10.1002/jnr.21829

10.1073/pnas.022575999

10.1002/(SICI)1097-4547(20000201)59:3<301::AID-JNR3>3.0.CO;2-H

10.1002/glia.10186

10.1038/sj.onc.1204984

Xu HL, 1999, Effects of 3‐n‐butylphthalide on production of vasoactive substances by cerebral and aortic endothelial cells, Acta Pharmacol Sin, 20, 929

10.1097/00005344-200406000-00018

Chang Q, 2003, Effects of chiral 3‐n‐butylphthalide on apoptosis induced by transient focal cerebral ischemia in rats, Acta Pharmacol Sin, 24, 796

10.1523/JNEUROSCI.18-19-07768.1998

10.1038/jcbfm.2009.44

10.1016/j.neuropharm.2010.09.025

10.1371/journal.pone.0038932

10.1016/0092-8674(89)90013-5

10.1111/j.1527-3458.2008.00042.x

10.1073/pnas.0401063101

10.1523/JNEUROSCI.15-07-04796.1995

10.1002/jnr.20561

10.1111/cns.12016

10.1016/j.ejphar.2009.08.036

10.1007/s00210-010-0575-9